Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598525 | 0.91 | TSHR (0.56) | TSHRHTTEP300DDB1CRBN | |
| SCHEMBL12272460 | 0.91 | TSHR (0.51) | TSHRHTTEP300DDB1CRBN | |
| SCHEMBL6823296 | 0.83 | HTR2A (0.50) | TSHRHTTEP300 | |
| SCHEMBL11857334 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17070917 | 0.78 | ALDH1A1 (0.57) | TSHRHTTEP300ALDH1A1MAPT | |
| SCHEMBL10655634 | 0.78 | HDAC8 (0.51) | DDB1CRBNGAAHDAC8 | |
| SCHEMBL20347921 | 0.77 | CES2 (0.47) | TSHRHTTEP300CES2 | |
| SCHEMBL1708540 | 0.76 | SLC6A2 (0.47) | TSHRHTTL3MBTL1CES2 | |
| SCHEMBL6865807 | 0.76 | DRD2 (0.39) | TSHRHTT | |
| SCHEMBL15617162 | 0.76 | TDP1 (0.41) | TSHRHTTMAPTL3MBTL1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038612-B1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3038612-B1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10351511-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351511-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-07-16 | — | — | US | disclosed |
| CN-105873577-B | Cycloalkenylamides as bromodomain inhibitors | 西奈山伊坎医学院 | 2019-06-18 | — | — | CN | disclosed |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-19 | — | — | US | disclosed |
| US-9884806-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884806-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-02-06 | — | — | US | disclosed |
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| EP-0994100-B1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | NIKKEN CHEMICALS CO LTD (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6780874-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATIVE AGENT | CELLTECH R & D LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
| US-6610700-B2 | Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example | CELLTECH R & D LIMITED (GB) | 2003-08-26 | — | — | US | disclosed |
| EP-1332132-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | TSHR 372/4885HTT 3826/4885EP300 647/4885 |
| US-10351511-B2 | Cyclic vinylogous amides as bromodomain inhibitors | BRD1, BRD4, BRDT | TSHR 3984/4885HTT 3022/4885EP300 6/4885 |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRDT | TSHR 3984/4885HTT 3022/4885EP300 6/4885 |
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | TSHR 320/4885HTT 3805/4885EP300 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.